EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

Danai Dima iD, Utkarsh Goel iD, Aishwarya Sannareddy iD, Nnaemeka Ibeh, Fauzia Ullah, Aimaz Afrough, Sandra Mazzoni iD, Ali Mehdi, Joslyn Rudoni, Shahzad Raza iD, Nicole De Simone, Louis Williams und 10 weitere

Hematological Oncology · 2024

DOI: 10.1002/hon.3293 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2024. Verfasst von Danai Dima und 21 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Plasma Exchange. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS ( p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPlasma ExchangeHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultAged, 80 and overKidney Diseases

Stichwörter der Autor:innen

cast nephropathydaratumumabmultiple myelomaplasmapheresistherapeutic plasma exchange

Autor:innen und Institutionen

  • Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.
  • University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Pathology and Laboratory Medicine, University of Texas, Houston, Texas, USA.
  • Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Sandra Mazzoni, Shahzad Raza, Adeel Khan, Faiz Anwer

Zitieren

APA

Dima, D., Goel, U., Sannareddy, A., Ibeh, N., Ullah, F., Afrough, A., Mazzoni, S., Mehdi, A., Rudoni, J., Raza, S., De Simone, N., Williams, L., Khan, A., Rashid, A., Rice, M., Ricci, K., Samaras, C., Valent, J., Anderson, L. D., …, & Khouri, J. (2024). Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematological Oncology. https://doi.org/10.1002/hon.3293

Vancouver

Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, et al. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematological Oncology. 2024. doi:10.1002/hon.3293

BibTeX
@article{Dima2024,
  author = {Dima, Danai and Goel, Utkarsh and Sannareddy, Aishwarya and Ibeh, Nnaemeka and Ullah, Fauzia and Afrough, Aimaz and Mazzoni, Sandra and Mehdi, Ali and Rudoni, Joslyn and Raza, Shahzad and De Simone, Nicole and Williams, Louis and Khan, Adeel and Rashid, Aliya and Rice, Mikhaila and Ricci, Kristin and Samaras, Christy and Valent, Jason and Anderson, Larry D and Anwer, Faiz and Kaur, Gurbakhash and Khouri, Jack},
  title = {Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3293}
}
Kostenlos starten →